+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06501482

Postoperative Reintroduction of FOLFIRI Chemotherapy Versus No Treatment After Resection of Colorectal Liver Metastases with Response to Preoperative FOLFIRI

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-09-09

254

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the benefit of reintroducing FOLFIRI-based chemotherapy after surgery in patients with colorectal liver metastases who responded well to preoperative FOLFIRI chemotherapy but could not receive oxaliplatin-based treatments due to contraindications. This national, multicenter, open-label phase III trial compares postoperative FOLFIRI chemotherapy to no treatment in patients who had up to 10 liver metastases removed and showed an objective response to their preoperative therapy. Participants in the experimental group will receive postoperative FOLFIRI chemotherapy consisting of irinotecan, leucovorin, and 5-FU given biweekly for a total of 12 cycles, including the preoperative treatment cycles. The control group will not receive any postoperative treatment. The study aims to assess whether reintroducing FOLFIRI improves the rate of disease-free survival three years after surgery compared to no additional treatment. During the trial, participants will be monitored for disease recurrence and survival outcomes over several years. Assessments include imaging to confirm no residual disease after surgery and evaluation of tumor response to prior therapy. Researchers will primarily measure the percentage of patients without disease recurrence at three years, along with overall survival and liver-specific survival rates. The study plans to enroll 254 patients and follow them for up to six years from the start of the trial.

CONDITIONS

Brief Title

Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI

Research Team

S

Stéphane BENOIST, MHD, PHD

A

Antoine BROUQUET, MHD, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here